IRE联合NK细胞治疗原发性肝癌的安全性和临床疗效

肝脏 ›› 2020, Vol. 25 ›› Issue (12): 1272-1274.

IRE联合NK细胞治疗原发性肝癌的安全性和临床疗效

张伟华, 秦艳青, 沈金杰

215101 江苏苏州市中西医结合医院肿瘤科

收稿日期:2020-05-03 出版日期:2020-12-31 发布日期:2021-02-26
通讯作者: 张伟华,Email:xiatiant21@163.com
基金资助:
江苏省自然科学基金资助项目(BK20181174)

Safety and clinical efficacy of IRE ablation combined with NK cells in the treatment of primary liver cancer

ZHANG Wei-hua, QIN Yan-qing, SHEN Jin-jie

Department of Oncology, Suzhou Integrated Hospital of Traditional Chinese and Western Medicine, Jiangsu 215101, China

Received:2020-05-03 Online:2020-12-31 Published:2021-02-26
Contact: ZHANG Wei-hua,Email:xiatiant21@163.com

摘要/Abstract

摘要： 目的探讨不可逆电穿孔(IRE)联合同种异体NK细胞免疫治疗原发性肝癌的安全性和近期疗效。方法选取2017年1月至2019年8月于本医院诊治的原发性肝癌患者 80例为研究对象,80名患者分为IRE组(n=40)和IRE-NK组(n=40)。记录患者所经历的所有不良事件;评估肿瘤生物标记物(AFP),循环肿瘤细胞(CTCs)、淋巴细胞数量和功能、生活质量、临床反应、无进展生存率(PFS)和总生存率(OS)的变化。结果联合治疗组PFS和OS的均值明显大于单纯IRE组(P<0.05)。IRE联合NK细胞免疫治疗可显著降低CTCs,提高免疫功能和Karnofsky功能状态。结论本研究提示了一种新的、有前途的联合治疗方法,即IRE和异体NK细胞免疫疗法。需要更大规模的临床试验来证实这些结论。

关键词: IRE, NK细胞, 原发性肝癌, 临床疗效

Abstract: Objective To investigate the safety and short-term efficacy of irreversible electroporation (IRE) combined with allogenic natural killer (NK) cell immunotherapy in the treatment of patients with unresectable primary liver cancer.Methods Between January 2017 and August 2019,80 patients were enrolled and randomly allocated to either the IRE group (n=40) or the IRE-NK group (n=40). All adverse events experienced by the patients were recorded; the changes in tumor biomarkers [AFP, circulating tumor cells (CTCs)], lymphocyte number and function, quality of life, clinical response, progression-free survival (PFS) and overall survival (OS) were assessed.Results Patients who received combination therapy exhibited significantly longer median PFS and OS than who just received IRE (P<0.05). The combination therapy of IRE and NK cell immunotherapy significantly reduced CTCs and increased immune function and Karnofsky performance status.Conclusion Our data suggest a novel, promising combination therapy using IRE and allogenic NK cell immunotherapy. Larger clinical trials are required to con?rm these conclusions.

Key words: Irreversible electroporation, Natural killer cells, Primary liver cancer, Clinical trial

张伟华, 秦艳青, 沈金杰. IRE联合NK细胞治疗原发性肝癌的安全性和临床疗效[J]. 肝脏, 2020, 25(12): 1272-1274.

ZHANG Wei-hua, QIN Yan-qing, SHEN Jin-jie. Safety and clinical efficacy of IRE ablation combined with NK cells in the treatment of primary liver cancer[J]. Chinese Hepatolgy, 2020, 25(12): 1272-1274.

参考文献

[1] 吕桂帅,陈磊,王红阳. 我国肝癌研究的现状与前景. 生命科学, 2015, 27: 237-248.
[2] 魏矿荣,彭侠彪,梁智恒,等. 全球肝癌流行概况. 中国肿瘤, 2015, 24: 621-630.
[3] 龚杰,宋云,徐尔侃,等. 肝癌的临床治疗新进展. 肝胆胰外科杂志, 2016, 28: 522-525.
[4] 杨玉媚,杜端明,陈继冰,等. 不可逆电穿孔消融治疗前列腺癌5例. 介入放射学杂志, 2018, 27: 854-859.
[5] Lin M, Liang S, Wang X, et al. Shortterm clinical ef?cacy of percutaneous irreversible electroporation combined with allogeneic natural killer cell for treating metastatic pancreatic cancer. Immunol Lett, 2017, 186: 20-27.
[6] Appelbaum L, Ben-David E, Faroja M, et al. Irreversible electroporation ablation: creation of large-volume ablation zones in in vivo porcine liver with fourelectrode arrays. Radiology, 2014,270:416-424.
[7] 孙钢. 不可逆电穿孔技术消融肿瘤研究进展. 介入放射学杂志, 2015, 24: 277-281.
[8] 姚陈果,赵亚军,李成祥,等. 不可逆电穿孔微创消融肿瘤技术的研究进展. 高电压技术, 2014, 40: 3725-3737.
[9] 任海龙,邵东燕,李琦,等. NK细胞应用于肿瘤免疫治疗的研究进展. 现代免疫学, 2017, 37: 233-237.
[10] 魏海荣,田志刚. NK细胞活化/抑制受体在慢性乙肝病毒感染中的发生发展//中国免疫学会第五届全国代表大会暨学术会议论文摘要. 中国江苏镇江: 20061.
[11] 孙玉英,孔繁华,奚永志. MHC结构与功能的研究进展. 中国实验血液学杂志, 2000: 227-230.
[12] Bulvik BE, Rozenblum N, Gourevich S, et al. Irreversible electroporation versus radiofrequency ablation: a comparison of local and systemic effects in a small-animal model. Radiology, 2016, 280: 413-424.
[13] 张伟洁,郑宏. IL-6介导免疫炎性反应作用及其与疾病关系的研究进展. 细胞与分子免疫学杂志, 2017, 33: 699-703.

[1]	徐新宝, 殷杰, 吉浩明, 钱俐. S-TACE联合阿帕替尼对中晚期原发性肝癌患者肿瘤血管因子、肝功能和预后的影响[J]. 肝脏, 2020, 25(9): 933-936.
[2]	胡素玲, 栗红江. SonoVue超声造影对不典型肝脏局灶性病灶的鉴别诊断价值[J]. 肝脏, 2020, 25(8): 835-836.
[3]	周艳珂, 王敬敏, 田婧, 李潜. 肝脏神经内分泌肿瘤与肝细胞癌超声学特征的差异比较[J]. 肝脏, 2020, 25(7): 686-688.
[4]	王骁, 周锡建, 顾培. 精确放疗治疗原发性肝癌后HBV再激活的影响因素研究[J]. 肝脏, 2020, 25(7): 702-704.
[5]	薛宏丽, 白晶, 单洪, 秦丽莉. HBsAg定量在乙型肝炎相关性肝癌患者中检测的临床意义[J]. 肝脏, 2020, 25(7): 743-745.
[6]	俞力, 刘苏. 瑞戈非尼靶向作用BRAF基因治疗原发性肝癌的机制研究[J]. 肝脏, 2020, 25(5): 513-516.
[7]	王家欢, 李震. ¹²⁵I放射粒子植入联合肝动脉栓塞术对原发性肝癌的疗效及对肝脏TRF1和TRF2表达影响[J]. 肝脏, 2020, 25(4): 402-406.
[8]	孙亮, 周旋, 刘桂治, 林茂锐, 李明友, 曹东林. 肝癌患者肠道微生态结构变化的特点分析[J]. 肝脏, 2020, 25(3): 267-269.
[9]	王雨, 许达峰, 周开伦, 武金才, 丁驿超, 古海强, 谢明微, 林明花. TLR4和肠道菌群在原发性肝癌进展中动态变化及与预后的关系[J]. 肝脏, 2020, 25(3): 273-276.
[10]	周友乾, 罗心晨, 邹喜荣, 李翠, 欧阳帆, 尹凤鸣. HBsAg阴性HBV相关原发性肝癌临床特点分析[J]. 肝脏, 2020, 25(3): 288-291.
[11]	余守江, 王国兴, 马兰芳. TACE联合微波消融对原发性肝癌患者肿瘤组织灌注、免疫功能及预后的影响[J]. 肝脏, 2020, 25(3): 294-296.
[12]	李彦伟. PCR检测HBV前C/C基因启动子区变异与肝细胞癌的关系[J]. 肝脏, 2020, 25(3): 300-301.
[13]	沈张平, 王钦君, 季沈杰. 血清miR127-3P与原发性肝癌的相关性研究[J]. 肝脏, 2020, 25(3): 302-305.
[14]	王家欢, 李震. 对比经皮射频消融术和经腹腔镜下肝切除术治疗Ⅰa期原发性肝癌的临床效果[J]. 肝脏, 2020, 25(2): 146-148.
[15]	何正阳, 商斌仪, 佘为民, 卓蕴慧. 中药联合TACE治疗原发性肝癌疗效的系统评价[J]. 肝脏, 2020, 25(12): 1262-1268.